APA (7th ed.) Citation

Rudin, C. M., Pietanza, M. C., Bauer, T. M., Ready, N., Morgensztern, D., Glisson, B. S., . . . Govindan, R. (2017). Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncology, 18(1), 42. https://doi.org/10.1016/S1470-2045(16)30565-4

Chicago Style (17th ed.) Citation

Rudin, Charles M., et al. "Rovalpituzumab Tesirine, a DLL3-targeted Antibody-drug Conjugate, in Recurrent Small-cell Lung Cancer: A First-in-human, First-in-class, Open-label, Phase 1 Study." Lancet Oncology 18, no. 1 (2017): 42. https://doi.org/10.1016/S1470-2045(16)30565-4.

MLA (9th ed.) Citation

Rudin, Charles M., et al. "Rovalpituzumab Tesirine, a DLL3-targeted Antibody-drug Conjugate, in Recurrent Small-cell Lung Cancer: A First-in-human, First-in-class, Open-label, Phase 1 Study." Lancet Oncology, vol. 18, no. 1, 2017, p. 42, https://doi.org/10.1016/S1470-2045(16)30565-4.